.

Deeper Knowledge, Faster

  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
US Army
Mallinckrodt
Federal Trade Commission
Daiichi Sankyo
Farmers Insurance
Dow
QuintilesIMS
McKinsey
AstraZeneca

Generated: June 27, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021087

« Back to Dashboard
NDA 021087 describes TAMIFLU, which is a drug marketed by Roche and is included in two NDAs. It is available from five suppliers. There are two patents protecting this drug and three Paragraph IV challenges. Additional details are available on the TAMIFLU profile page.

The generic ingredient in TAMIFLU is oseltamivir phosphate. There are seven drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the oseltamivir phosphate profile page.

Summary for NDA: 021087

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Pharmacology for NDA: 021087

Mechanism of ActionNeuraminidase Inhibitors

Suppliers and Packaging for NDA: 021087

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TAMIFLU
oseltamivir phosphate
CAPSULE;ORAL 021087 NDA Genentech, Inc. 0004-0800 0004-0800-85 1 BLISTER PACK in 1 CARTON (0004-0800-85) > 10 CAPSULE in 1 BLISTER PACK
TAMIFLU
oseltamivir phosphate
CAPSULE;ORAL 021087 NDA Genentech, Inc. 0004-0801 0004-0801-85 1 BLISTER PACK in 1 CARTON (0004-0801-85) > 10 CAPSULE in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 75MG BASE
Approval Date:Oct 27, 1999TE:ABRLD:Yes
Patent:5,763,483*PEDPatent Expiration:Feb 23, 2017Product Flag?Substance Flag?Delist Request?Y
Patent:5,866,601*PEDPatent Expiration:Aug 2, 2016Product Flag?Substance Flag?Delist Request?

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 45MG BASE
Approval Date:Jul 2, 2007TE:ABRLD:Yes
Patent:5,763,483*PEDPatent Expiration:Feb 23, 2017Product Flag?Substance Flag?Delist Request?Y

Expired Orange Book Patents for NDA: 021087

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Roche
TAMIFLU
oseltamivir phosphate
CAPSULE;ORAL021087-001Oct 27, 19995,866,601*PED► Subscribe
Roche
TAMIFLU
oseltamivir phosphate
CAPSULE;ORAL021087-001Oct 27, 19995,952,375*PED► Subscribe
Roche
TAMIFLU
oseltamivir phosphate
CAPSULE;ORAL021087-003Jul 2, 20075,763,483*PED► Subscribe
Roche
TAMIFLU
oseltamivir phosphate
CAPSULE;ORAL021087-003Jul 2, 20075,952,375*PED► Subscribe
Roche
TAMIFLU
oseltamivir phosphate
CAPSULE;ORAL021087-001Oct 27, 19995,763,483*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
US Department of Justice
AstraZeneca
Healthtrust
Covington
Boehringer Ingelheim
Julphar
Dow
QuintilesIMS
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot